Two approaches to construct mammalian expression vector of shRNA to reduce expression and replication of HBV in vitro.

Mol Biol Rep

Department of Medical Research, Guangzhou Liuhuaqiao Hospital, Liuhua Road 111, Guangzhou, Guangdong Province, P. R. China.

Published: September 2008

Two approaches have been developed to construct plasmids that mediate RNA interference to inhibit the replication and expression of HBV in 2.2.15 cell. The overlapping PCR extension and restriction enzyme-digestion were used to generate DNA fragments encoding designed shRNA based on sequences of ORF C of HBV genome. The pU6 derived vectors were constructed to develop plasmid based shRNA delivery systems termed pU6/HBVi. There were significant reductions in the expression of HBsAg and HBeAg between cells transfected with pU6/HBVi and control groups (as to HBsAg: P < 0. 01; and HBeAg: P < 0. 01). Consistently, the HBV DNA copies were reduced from 2.71 x 10(7) to <5 x 10(2) copies with or without pU6/HBVi. These results suggested that shRNA delivery by recombinant plasmids harboring shRNA encoding DNA fragment of interest generated either by overlapping PCR extension or restriction enzyme-digestion, could inhibit expressions of viral proteins and reduce viral replications. The pU6 derived plasmids might be a useful shRNA delivery system in mammalian cells. In addition, we found siRNA based on stealth 2311 was a potent RNAi target of HBV genome.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11033-007-9108-0DOI Listing

Publication Analysis

Top Keywords

hbsag hbeag
8
approaches construct
4
construct mammalian
4
expression
4
mammalian expression
4
expression vector
4
vector shrna
4
shrna reduce
4
reduce expression
4
expression replication
4

Similar Publications

Objectives: There is limited information comparing the off-therapy relapse rates of patients discontinued tenofovir alafenamide (TAF) to those stopping entecavir or tenofovir disoproxil fumarate (TDF).

Methods: A total of 805 HBeAg-negative patients without cirrhosis receiving entecavir (n=406), TDF (n=260) or TAF (n=139) were enrolled. Propensity-score (PS) matching method was applied to eliminate the significant differences in clinical characteristics.

View Article and Find Full Text PDF

Rationale: Mass vaccination, low cost of immunoglobulins, and new drugs led to the emergence of new, unusual patterns of hepatitis B serum markers. This study reported a rare case of hepatitis B with all 5 positive serum markers, including HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb.

Patient Concerns: A 30-year-old female patient was admitted due to abnormal liver function.

View Article and Find Full Text PDF

Three compounds, including a novel quinolizidine alkaloid, ochrocephalamine G (), were isolated from . Structural elucidation was achieved through spectroscopic analysis and electronic circular dichroism. Biological assays showed that ochrocephalamine G (100 μM) inhibited HBsAg and HBeAg by 8.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!